Shopping Cart
- Remove All
- Your shopping cart is currently empty
BKIDC-1553, an orally active antiglycolytic agent and bumped kinase inhibitor-derived compound, has a predicted half-life of approximately 17 hours in humans. It inhibits CYP2C8 and Angiotensin Converting Enzyme, making it suitable for cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | BKIDC-1553, an orally active antiglycolytic agent and bumped kinase inhibitor-derived compound, has a predicted half-life of approximately 17 hours in humans. It inhibits CYP2C8 and Angiotensin Converting Enzyme, making it suitable for cancer research [1]. |
In vitro | BKIDC-1553 (1.25-20 μM, 72 h) inhibits cell proliferation in various human prostate cancer cell lines in a dose-dependent manner [1]. |
In vivo | BKIDC-1553, administered orally at 20 mg/kg three times per week for four weeks, reduces tumor growth in LuCaP 35 patient-derived xenograft mice with human prostate cancer after five weeks [1]. |
Molecular Weight | 389.45 |
Formula | C22H23N5O2 |
Cas No. | 1951431-34-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.